P
Proscia
Biotech & Life Sciences · Philadelphia, United States · Founded 2014
Developer of pathology cloud technology for use in medicine MoreLess
A software company that develops and commercializes a digital pathology platform, Concentriq, to accelerate pathology's transformation toward a data-driven discipline. The platform is designed for image and workflow management in laboratory settings, with a focus on cancer diagnosis and research.
The business model is based on providing software as a service (SaaS) to clinical and research laboratories. The company's target clients include anatomic pathology laboratories, contract research organizations (CROs), and pharmaceutical and biotechnology companies. Proscia operates in the digital pathology market, which is a segment of the broader healthcare technology industry.
The company generates revenue through subscriptions to its Concentriq platform and its AI-powered applications. These applications are designed to improve the efficiency and accuracy of pathology workflows, ultimately aiming to enhance patient outcomes in areas like oncology.
Keywords: digital pathology, cancer diagnosis, AI, workflow management, precision medicine, SaaS, healthcare technology, oncology, image analysis, laboratory automation
Talent graph
Proscia's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Proscia has talent and traffic
team presence
across markets
Market sentiment
What the market is saying about Proscia
An AI-synthesized read of the highest-engagement posts about Proscia on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Proscia on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.













